The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI).
 
Hewitt Chang
No Relationships to Disclose
 
Luchia Andemicael
No Relationships to Disclose
 
Moshiur Mekhail Anwar
Stock and Other Ownership Interests - Fidelity Investments; Incyte
Patents, Royalties, Other Intellectual Property - I hold a patent for intraoperative imaging technology and am co-inventor on an implantable radiation sensor.; Patent on ultrasound based medical device therapeutics.
 
John Gordan
Consulting or Advisory Role - Genentech/Roche
Research Funding - ShangPharma Innovation (Inst)
Patents, Royalties, Other Intellectual Property - A small molecule patent has been submitted for a tool compound developed in my academic research, and is currently in provisional form. It has no current health applications but may eventually be developed into a clinically relevant compound. (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Jamese Johnson
No Relationships to Disclose
 
Bridget P Keenan
Employment - Astellas Pharma (I)
Research Funding - Partner Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis/Ipsen (Inst); Kinnate Biopharma; Merck (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
 
Andrew H. Ko
Honoraria - BioAscent; Clinical Care Options; Gerson Lehrman Group; Medscape; MJH Life Sciences; Research to Practice
Consulting or Advisory Role - ERYTECH Pharma; Five Prime Therapeutics; Imugene; Ipsen; Roche/Genentech; Signatera; SynCoreBio; Syros Pharmaceuticals; Turning Point Therapeutics; Tyme
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CrystalGenomics (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Merck (Inst)
 
Katherine Van Loon
Research Funding - Celgene (Inst)
 
Alan P. Venook
Consulting or Advisory Role - Amgen; Bayer Health; BridgeBio Pharma; Bristol-Myers Squibb Foundation/Janssen; Exact Sciences; Exelixis; Gilead Sciences; GlaxoSmithKline; Merck Sharp & Dohme; Pfizer
Research Funding - Amgen
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; Alector; Atreca; BioAtla; Bolt Biotherapeutics; ImmunoGenesis; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; SOTERIA Precision Medicine; Sutro Biopharma
Consulting or Advisory Role - Alector; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Dendreon; EMD Serono; Innovent Biologics; Janssen Oncology; Merck; Nutcracker Therapeutics, Inc.; RAPT Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Melody Ju Xu
No Relationships to Disclose
 
Mary Uan-Sian Feng
Leadership - Artera (I); PFS Genomics (I); Serimmune (I)
Stock and Other Ownership Interests - Artera (I); PFS Genomics (I); Serimmune (I)
Consulting or Advisory Role - Astellas Pharma (I); AstraZeneca; Bayer (I); Blue Earth Diagnostics (I); BMS (I); Exact Sciences (I); Foundation Medicine (I); Janssen Oncology (I); Myovant Sciences (I); Novartis (I); SerImmune (I); Varian Medical Systems (I)
Research Funding - AstraZeneca (Inst); Varian Medical Systems (Inst); Zenith Epigenetics (I)
Patents, Royalties, Other Intellectual Property - Helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, his employer at the time. It is in the process of being licensed to PFS Genomics, a company he helped fou (I); UpToDate